LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
Background Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tum...
Main Authors: | Ting Li, Wei Li, Ying Li, Sui Chen, Qian Gao, Xiaopeng Li, Po Zhang, Jinyang Hu, Feng Dong, You He, Xianyou Xia, Fangling Cheng, Xiaoshuang Hou, Guohao Liu, Minhai Dong, Qungen Xiao, Xingjiang Yu, Guifa Xi, Dongsheng Guo, Xudong Wu, Baofeng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/9/e004452.full |
Similar Items
-
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma
by: Fangling Cheng, et al.
Published: (2019-06-01) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
by: Jinyang Hu, et al.
Published: (2020-11-01) -
Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth
by: Youwei Li, et al.
Published: (2023-01-01) -
Lrig1 regulates the balance between proliferation and quiescence in glioblastoma stem cells
by: Kirsty M. Ferguson, et al.
Published: (2022-10-01) -
LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma
by: Chenghao Peng, et al.
Published: (2021-02-01)